EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Clinical Characteristics of Patients With Anti‐Signal Recognition Particle Antibody: A Cohort Study

Ameen Jubber, Maumer Durrani, Abdullah Almayahi, Kehinde Sunmboye iD

Immunity, Inflammation and Disease · 2026

DOI: 10.1002/iid3.70297 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Ameen Jubber und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Signal Recognition Particle, Autoantibodies, Myositis. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐signal recognition particle (anti‐SRP) antibodies are myositis‐specific autoantibodies associated with immune‐mediated necrotizing myopathy. This study was undertaken to better understand how patients with anti‐SRP antibodies have been managed at our tertiary centre and to assess the spectrum of clinical features and outcomes in routine clinical practice.

Methods

We conducted a retrospective evaluation of 25 patients with anti‐SRP antibodies identified via line‐blot immunoassay at a tertiary care centre (2019–2024). Demographic, clinical, serological, and imaging data were reviewed.

Results

The group of patients had a mean age of 60.1 years, with a female‐to‐male ratio of 10:15. Eight patients (32%) were diagnosed with myositis, primarily presenting with proximal muscle weakness. Interstitial lung disease was observed in 53% of the group of patients, and 50% of the subset of patients with myositis. Coexisting myositis‐specific autoantibodies were present in 32%, and 48% had positive antinuclear antibody titres (≥ 1:400). Cardiac involvement was reported in two myositis patients. Corticosteroids, often combined with mycophenolate mofetil or other immunosuppressants, formed the basis of treatment.

Conclusion

Anti‐SRP antibodies are associated with a heterogeneous clinical spectrum, with many patients lacking myositis features. There was a high prevalence of coexisting autoantibodies. Further studies are needed to elucidate the pathogenic role of anti‐SRP and optimise management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal Recognition ParticleAutoantibodiesMyositisHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultLung Diseases, InterstitialAdrenal Cortex HormonesImmunosuppressive Agents

Stichwörter der Autor:innen

anti‐SRP antibodyextramuscular manifestationsimmune mediated necrotizing myopathyinflammatory myopathyinterstitial lung diseasemyositis‐specific autoantibodies

Substanzen

Signal Recognition ParticleAutoantibodiesAdrenal Cortex HormonesImmunosuppressive Agents

Autor:innen und Institutionen

  • University Hospitals of Leicester, Leicester, UK.
  • University of Leicester, Leicester, UK.

ORCID-Profile: Kehinde Sunmboye

Zitieren

APA

Jubber, A., Durrani, M., Almayahi, A., & Sunmboye, K. (2026). Clinical Characteristics of Patients With Anti‐Signal Recognition Particle Antibody: A Cohort Study. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70297

Vancouver

Jubber A, Durrani M, Almayahi A, Sunmboye K. Clinical Characteristics of Patients With Anti‐Signal Recognition Particle Antibody: A Cohort Study. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70297

BibTeX
@article{Jubber2026,
  author = {Jubber, Ameen and Durrani, Maumer and Almayahi, Abdullah and Sunmboye, Kehinde},
  title = {Clinical Characteristics of Patients With Anti‐Signal Recognition Particle Antibody: A Cohort Study},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  doi = {10.1002/iid3.70297}
}
Kostenlos starten →